These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 9550373

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T, Zhang QJ, Levitskaya J, Coram M, Kurilla MG, Masucci MG.
    Int J Cancer; 1996 Oct 09; 68(2):251-8. PubMed ID: 8900437
    [Abstract] [Full Text] [Related]

  • 4. CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines.
    Frisan T, Donati D, Cervenak L, Wilson J, Masucci MG, Bejarano MT.
    Int J Cancer; 1999 Dec 10; 83(6):772-9. PubMed ID: 10597194
    [Abstract] [Full Text] [Related]

  • 5. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.
    Khanna R, Burrows SR, Thomson SA, Moss DJ, Cresswell P, Poulsen LM, Cooper L.
    J Immunol; 1997 Apr 15; 158(8):3619-25. PubMed ID: 9103423
    [Abstract] [Full Text] [Related]

  • 6. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R, Burrows SR, Suhrbier A, Jacob CA, Griffin H, Misko IS, Sculley TB, Rowe M, Rickinson AB, Moss DJ.
    J Immunol; 1993 Jun 01; 150(11):5154-62. PubMed ID: 7684421
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP, Thomas WA, Blake NW, Rickinson AB.
    Eur J Immunol; 1996 Aug 01; 26(8):1875-83. PubMed ID: 8765034
    [Abstract] [Full Text] [Related]

  • 10. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F, Sforza F, Sicurella M, Marescotti D, Gallerani E, Baldisserotto A, Marastoni M, Gavioli R.
    Immunology; 2011 May 01; 133(1):105-14. PubMed ID: 21342184
    [Abstract] [Full Text] [Related]

  • 11. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R, Burrows SR, Moss DJ, Silins SL.
    J Virol; 1996 Aug 01; 70(8):5357-62. PubMed ID: 8764046
    [Abstract] [Full Text] [Related]

  • 12. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP, Constandinou CM, Thomas WA, Croom-Carter D, Blake NW, Murray PG, Crocker J, Rickinson AB.
    Blood; 1998 Aug 01; 92(3):1020-30. PubMed ID: 9680372
    [Abstract] [Full Text] [Related]

  • 13. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G, Mayrhofer S, Taylor G, Haigh T, Leese A, Rickinson A, Blake N.
    J Exp Med; 2001 Oct 15; 194(8):1053-68. PubMed ID: 11602636
    [Abstract] [Full Text] [Related]

  • 14. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1.
    Henriquez NV, Floettmann E, Salmon M, Rowe M, Rickinson AB.
    J Immunol; 1999 Mar 15; 162(6):3298-307. PubMed ID: 10092782
    [Abstract] [Full Text] [Related]

  • 15. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF.
    Blood; 1998 Oct 01; 92(7):2477-83. PubMed ID: 9746788
    [Abstract] [Full Text] [Related]

  • 16. T cells can induce somatic mutation in B cell receptor-engaged BL2 Burkitt's lymphoma cells independently of CD40-CD40 ligand interactions.
    Denépoux S, Fournier N, Péronne C, Banchereau J, Lebecque S.
    J Immunol; 2000 Feb 01; 164(3):1306-13. PubMed ID: 10640744
    [Abstract] [Full Text] [Related]

  • 17. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R, Burrows SR, Steigerwald-Mullen PM, Moss DJ, Kurilla MG, Cooper L.
    Int Immunol; 1997 Oct 01; 9(10):1537-43. PubMed ID: 9352359
    [Abstract] [Full Text] [Related]

  • 18. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
    Griffin H, Rowe M, Murray R, Brooks J, Rickinson A.
    Eur J Immunol; 1992 Jul 01; 22(7):1741-8. PubMed ID: 1378014
    [Abstract] [Full Text] [Related]

  • 19. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.
    Wang F, Li X, Annis B, Faustman DL.
    Hum Gene Ther; 1995 Aug 01; 6(8):1005-17. PubMed ID: 7578413
    [Abstract] [Full Text] [Related]

  • 20. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
    Masucci MG, Klein E.
    Semin Cancer Biol; 1991 Feb 01; 2(1):63-71. PubMed ID: 1655115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.